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ABSTRACT
Background Several recessive Mendelian disorders are
common in Europeans, including cystic ﬁbrosis (CFTR),
medium-chain-acyl-Co-A-dehydrogenase deﬁciency
(ACADM), phenylketonuria (PAH) and alpha 1-antitrypsin
deﬁciency (SERPINA1).
Methods In a multicohort study of >19 000 older
individuals, we investigated the relevant phenotypes in
heterozygotes for these genes: lung function (forced
expiratory volume in 1 second (FEV1), forced vital
capacity (FVC)) for CFTR and SERPINA1; cognitive
measures for ACADM and PAH; and physical capability
for ACADM, PAH and SERPINA1.
Results Findings were mostly negative but lung
function in SERPINA1 (protease inhibitor (PI) Z allele,
rs28929474) showed enhanced FEV1 and FVC (0.13 z-
score increase in FEV1 (p=1.7×10−5) and 0.16 z-score
increase in FVC (p=5.2×10−8)) in PI-MZ individuals.
Height adjustment (a known, strong correlate of FEV1
and FVC) revealed strong positive height associations of
the Z allele (1.50 cm increase in height (p=3.6×10−10)).
Conclusions The PI-MZ rare (2%) SNP effect is nearly
four times greater than the ‘top’ common height SNP in
HMGA2. However, height only partially attenuates the
SERPINA1-FEV1 or FVC association (around 50%) and
vice versa. Height SNP variants have recently been
shown to be positively selected collectively in North
versus South Europeans, while the Z allele high
frequency is localised to North Europe. Although PI-ZZ is
clinically disadvantageous to lung function, PI-MZ
increases both height and respiratory function;
potentially a balanced polymorphism. Partial blockade of
PI could conceivably form part of a future poly-
therapeutic approach in very short children. The notion
that elastase inhibition should beneﬁt patients with
chronic obstructive pulmonary disease may also merit re-
evaluation. PI is already a therapeutic target: our
ﬁndings invite a reconsideration of the optimum level in
respiratory care and novel pathway potential for
development of agents for the management of growth
disorders.
INTRODUCTION
Heterozygote carriers for recessive Mendelian
(monogenic) disorders such as cystic ﬁbrosis (MIM:
219700), medium-chain-acyl-Co-A-dehydrogenase
deﬁciency (MIM: 201450), phenylketonuria
(MIM: 261600) and alpha 1-antitrypsin (AAT)
deﬁciency (MIM: 613490) are relatively common
in the UK population (1.5% (ACADM) to ∼10%
(protease inhibitor (PI)-MS)). Unlike in homozy-
gote carriers, no clinical features are evident in het-
erozygotes although biochemical phenotype may be
detectable (eg, phenylalanine level after aspartame1
(PAH)). The AAT deﬁciency phenotype is continu-
ous across the six genotypes of the S and Z alleles
(MM wildtype, MS, MZ, SS, SZ and ZZ).
However, only individuals of ZZ genotype are
notable clinically; the condition results in
early-onset lung emphysema with a penetrance of
60% for ZZ individuals.2 There is no clear associ-
ation in the literature between lung disease and
individuals with either MZ3 or SZ genotype.4
The preﬁx PI is added to the allele or genotype
name. According to this, the normal (most
common) allele is PI-M and the most common
pathogenic allele is PI-Z. Mendelian disease alleles
such as PI-Z may be prevalent in a population
through new mutation and chance, with insufﬁcient
time for ﬁtness and selection to take effect, or
through balancing selection where heterozygote
advantage outweighs homozygote disadvantage.
A textbook example of the latter is sickle cell
anaemia where resistance to malaria confers a
heterozygote advantage.
Within the Healthy Ageing across the Life
Course (HALCyon) collaboration5 6 of UK observa-
tional cohorts, we tested whether heterozygote car-
riers for these four Mendelian diseases exhibit
phenotypic differences from non-carriers in later
life. In eight studies, we genotyped the deltaF508
mutation for cystic ﬁbrosis, the K340E mutation
for medium-chain-acyl-Co-A-dehydrogenase deﬁ-
ciency, the three most common phenylketonuria
mutations in the UK (rs5030861, rs5030858 and
rs75193786 (T to C mutation)) and lastly
rs28929474 and rs17580 representing PI-Z and
PI-S alleles, respectively, to infer AAT PI genotypes.
Lung function, cognitive capability and physical
capability are complex traits that have each been
shown to predict mortality.7–9 For homozygotes or
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compound heterozygotes of these four Mendelian diseases,
large differences in earlier life are seen for lung function (CFTR,
SERPINA1) and cognitive function (ACADM, PAH). We tested
heterozygotes against equivalent later life traits accordingly, with
an additional analysis of physical capability (ACADM, PAH and
SERPINA110). To generate estimates using all of the individual
participant data (IPD), we pooled IPD into a single data set and
conducted one-step meta-analyses of the harmonised outcomes.
This is superior to a conventional two-step approach (analyses
performed within each cohort and study-speciﬁc estimates
pooled in a meta-analysis) when the exposure is rare.11 12
A well-known signature of recent selection in humans is the
very fast increase in frequency of the favoured allele (or haplo-
type) in a population.13 Two haplotype-based tests can detect it:
the extended haplotype homozygosity (EHH) test14 and the
integrated test iHS.13 Rare haplotypes are also informative. It
has been suggested15 that reduced decay of EHH of haplotypes
that are both rare and extended is informative to identify signa-
tures of natural selection. These signatures could reﬂect either
residual levels of an older selection phenomenon that is being
diluted or an active process of natural selection.15 We performed
an EHH analysis of rs28929474 and rs17580 using genome-
wide association study (GWAS) data and PI genotype status in a
UK cohort, ALSPAC.16 We also tested selection related to
common variation around SERPINA1 from Haplotter13 and
estimated allele age based both on allele frequency17 and on
local recombination between the Z locus and other SNPs in the
ALSPAC data.
MATERIALS AND METHODS
A list of acronyms used in this article is shown in table 1.
HALCyon
Study participants
Individuals included in this analysis belonged to the HALCyon
collaboration.5 We meta-analysed IPD from eight UK cohorts:
the Boyd Orr Cohort, the Caerphilly Prospective Study (CaPS),
the English Longitudinal Study of Ageing (ELSA), the
Hertfordshire Ageing Study (HAS), the Hertfordshire Cohort
Study, the Lothian Birth Cohort 1921 (LBC1921), the MRC
National Survey of Health and Development (NSHD) and the
Whitehall II Study (WHII). Further information about the
HALCyon cohorts can be found in earlier publications.18
Mutation selection
We selected the most common causal mutation to genotype for
medium-chain acyl Co-A dehydrogenase deﬁciency
(rs77931234, otherwise known as K304E or c.985A>G19) and
cystic ﬁbrosis (the deltaF508 mutation, rs113993960).
With the exception of the NSHD cohort, we inferred AAT PI
status using the genotypes from rs28929474 and rs17580.
PI-MM corresponds to an individual who is wildtype for both
rs28929474 and rs17580. PI-MS individuals are wildtype for
rs28929474 and heterozygous for rs17580, while PI-MZ indivi-
duals are the converse. PI-SS individuals are homozygous for
rs17580 and wildtype for rs28929474, while PI-SZ individuals
are heterozygous for both SNPs. PI-ZZ individuals are wildtype
for rs17580 and homozygous for rs28929474. Due to their
rarity, age and very close recombination distance, other geno-
typic combinations of rs28929474 and rs17580 would be van-
ishingly rare. In the NSHD, we analysed PI status measured
from isoelectric focusing.20
Mutation selection was more complex for phenylketonuria
because several hundred causal mutations have been identiﬁed
to date. We selected rs5030861 (IVS12+1 G>A), rs5030858
(R408W) and rs75193786 [T to C mutation] (I65T) after con-
sulting a review of PKU mutations in Europe21 and the PAH
database22 (http://www.pahdb.mcgill.ca) and considering muta-
tions with highest frequency in UK populations.
Genotyping
Genotyping was performed by LGC Genomics (http://www.
lgcgenomics.com/), with the exception of rs17580 and
rs28929474 in ELSA and WHII for which genotype data were
already available. We inferred rs17580 and rs28929474 geno-
types in the NSHD using PI classes from isoelectric focusing.20
Further information on the genotyping quality is provided in
online supplementary table S1.
Harmonisation of outcomes and exposures by cohort
Wave of outcome assessment is detailed in online supplementary
appendix S2. All core continuous outcomes (lung function, cog-
nitive capability and physical capability) were transformed to
z-scores by subtracting the mean and dividing by the SD of the
measure within cohorts using all data available. All outcomes
were further harmonised across cohorts before z-scoring, as
detailed in online supplementary appendix S3.
Chronic obstructive pulmonary disease (COPD) status was
determined using the Global Lungs Initiative ERS Task Force
2012 regression equations, which derive the lower limit of
normal (LLN, 5th centile) values for forced expiratory volume
in 1 second (FEV1) and FEV1/forced vital capacity (FVC) ratio
given an individual’s age, sex and height.23 These specify that
age should be to at least one decimal place. This was not pos-
sible in ELSA, and thus, this may have introduced some error
into the prediction equation. In addition, COPD status is
derived in this analysis based on absolute FEV1 and FVC values
rather than standardised values. Recent studies24 have conﬁrmed
that different apparatus are likely to result in systematic differ-
ences in lung function readings, which our categorisation of
Table 1 List of acronyms
Gene acronyms
ACADM Acyl-CoA dehydrogenase, C-4 to C-12 straight chain
CFTR Cystic fibrosis transmembrane conductance regulator
HMGA2 High mobility group AT-hook 2
PAH Phenylalanine hydroxylase
SERPINA1 Serpin peptidase inhibitor, clade A (alpha-1 antiproteinase,
antitrypsin), member 1
Outcome acronyms
FEV1 Forced expiratory volume in 1 second
FVC Forced vital capacity
FCRT Four choice reaction time
Disease acronyms
PKU Phenylketonuria
MCADD Medium-chain-acyl-Co-A-dehydrogenase deficiency
Cohort acronyms
BO Boyd Orr
CaPS Caerphilly Prospective Study
ELSA English Longitudinal Study of Ageing
LBC1921 Lothian Birth Cohort 1921
HAS Hertfordshire Ageing Study
HALCyon Healthy Ageing across the Life Course
HCS Hertfordshire Cohort Study
NSHD MRC National Survey of Health and Development
WHII Whitehall II Study
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cases and non-cases for COPD has not taken into account. An
individual was classed as having COPD if their FEV1/FVC ratio
and their FEV1 were below the sex, height and age-speciﬁc
LLN. This identiﬁed approximately 8% of individuals as having
COPD, which indicated false positives as we would expect 5%.
Carrier status was deﬁned as a binary variable in all analyses
and was coded as [0] non-carrier and [1] carrier. The three PAH
mutations were combined so that a non-carrier was homozygous
for all three SNPs and a carrier was heterozygous for at least
one SNP. In the analysis of PI status, separate analyses were con-
ducted for PI-MS, PI-MZ, PI-SS, PI-SZ and PI-ZZ versus
PI-MM (with PI-MM coded as 0).
Several of the outcomes were transformed prior to z-scoring
to improve the normality of the residual distributions. Four
choice reaction time in CaPS was inverse transformed, search
speed was natural log transformed (NSHD and ELSA) and Mill
Hill was squared in WHII.
Analyses of FVC were repeated with a square-root transform-
ation and of FEV1/FVC ratio with a cube transformation.
Analyses of weight and body mass index (BMI) were repeated
with a natural log transformation, although these anthropomet-
ric outcomes were not z-scored.
Prior to analysis, individuals of non-European ancestry (self-
reported or detected from genome-wide data) and related indi-
viduals were removed from the data set.
Statistical analyses
All analyses were conducted using Stata v.13.125 and basic
covariates were age in years and sex. Analyses considering
additional covariates or conducted within strata were
restricted to individuals with these covariates/information
available.
The analysis of lung function by AAT PI status tested for a
linear association between binary PI status (PI-MS, MZ, SS, SZ,
ZZ vs PI-MM) and (1) FEV1, (2) FVC and (3) FEV1/FVC ratio.
Analyses were repeated in current, ex and never smokers and in
individuals classiﬁed as having COPD. Associations in all indivi-
duals were repeated with adjustment for (1) height and
height-squared and (2) height, height-squared and height-cubed.
Associations in COPD cases were also repeated with simultan-
eous adjustment for height, height-squared and smoking status.
The analysis of physical capability by AAT PI status tested for
association of binary PI-status with continuous or binary
outcome, adjusted for age and sex.
To explore the change in effect of PI status on lung function
following height adjustment, we tested for association of PI
status with height (cm), weight (kg) and BMI (kg/m2).
Associations with height were repeated with simultaneous
adjustment for FEV1 and FVC.
The analysis of lung function for CFTR tested for an associ-
ation of deltaF508 carrier status with FEV1, FVC and FEV1/
FVC ratio in all individuals adjusted for age and sex, and strati-
ﬁed by smoking status. We also repeated the analysis in indivi-
duals classiﬁed as cases for COPD. The analysis in all
individuals was repeated with simultaneous adjustment for
height and height-squared.
We also tested for association of PI status (in the usual
approach of PI-MS, MZ, SS, SZ, ZZ vs PI-MM) or deltaF508
carrier status with COPD case status.
The analysis of physical and cognitive capability outcomes for
PAH and ACADM tested for an association of mutation carrier
status with continuous or binary outcome, adjusted for age and
sex.
Within-cohort analyses
To produce estimates by cohort, linear regression was imple-
mented for continuous outcomes and logistic regression for
binary outcomes.
One-step meta-analysis
A one-step meta-analysis approach using the IPD from all eight
cohorts was used to derive estimates of effect sizes across all
studies. This approach was adopted rather than the two-step
method because the mutations are rare and thus the exposure of
interest (carrier status) was often a rare event in the cohorts.
One-step meta-analyses are based on the exact likelihood for the
data, do not assume a normal distribution of effect estimates
and do not assume that the SE of the effect estimate is exact;
they are thus more appropriate in this instance.11 12 A ﬁxed
effects (FE) or a random effects (RE) meta-analysis can be
implemented within the one-step framework. We ﬁrst imple-
mented an RE meta-analysis (as described below) in all associa-
tions due to the heterogeneity in study characteristics (age, sex,
geographical location). An RE model assumes that the true
effect of interest differs across the populations from which the
studies are sampled and estimates the average effect.
To implement a one-step RE meta-analysis for continuous
outcomes, we used the following command in Stata
mixed outcome binary_genetic_exposure i.study study#c.age
study#sex || study: binary_genetic_exposure, noconstant resi-
duals(independent, by(study)).
This mixed model tests for an RE of carrier status by cohort.
The ﬁxed portion of the model includes adjustment within
cohorts for age and sex, and an intercept by cohort. Residuals
are modelled to have study-speciﬁc distributions. A random
intercept is not assumed.
To implement a one-step RE meta-analysis for binary out-
comes, we used the following command in Stata
meqrlogit outcome binary_genetic_exposure i.study study#c.
age study#sex || study: binary_genetic_exposure, noconstant.
This similarly tests for a random carrier effect by cohort, with
covariate adjustment within cohorts in the ﬁxed part of the
model.
The corresponding mathematical model for the continuous
outcomes, with β coefﬁcients for FEs and u coefﬁcients for REs,
as per the nomenclature in the Stata Reference Manual26 for
mixed is
Outcomeij ¼ b0 þ b1j þ b2j ageij þ b3j sexij þ b4 carrierij
þ u5j carrierij þ 1ij
where εij is the normally distributed residual term with mean 0
and cohort speciﬁc variance and u5j is the random carrier effect
by cohort with mean 0 and variance estimated by the model.
The corresponding mathematical model26 for the binary out-
comes is
logit ðPrðOutcomeij ¼ 1ÞÞ
¼ b0 þ b1j þ b2j ageij þ b3j sexij þ b4 carrierij
þ u5j carrierij
In practice, we generally found that the estimated variance of
the random component of the carrier status effect (the add-
itional effect by cohort) was negligibly small. An FE model was,
therefore, more appropriate. The results presented in the main
tables also include an FE model using linear regression for
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continuous outcomes and logistic regression for binary out-
comes, pooling all of the data across cohorts, and including a
dummy variable for study. In all FE models, the covariates were
again included as factor variables to adjust for effects by cohort
(as would be the approach in a standard two-step meta-analysis).
For completeness, all tables provide the RE and the FE estimates
in addition to the estimated variance of the random carrier
effect for interpretation. While the variance of the RE is inform-
ative as to whether the genotypic effect was the same across
cohorts, it should also be noted that the RE model for continu-
ous outcomes assumed heteroscedastic residuals (by cohort)
while the FE model used a simpliﬁcation of homoscedastic resi-
duals. In a two-step framework, heteroscedastic residuals are
modelled because associations are implemented within studies
before meta-analysis of the effect estimates. Our main results
were robust to either implementation. For the binary outcomes
of COPD status and ability to balance, we make the simplifying
assumption of independent and identically distributed residuals
across cohorts.
The within-cohort estimates are provided for completeness,
but these often analyse a rather small number of heterozygotes
(or PI-MS, MZ, SS, SZ, ZZ). The meta-analysed estimates are
the most reliable as these pool the data to maximise the sample
size of the carriers. Online supplementary table S2, which
details sample size for the meta-analyses by outcome, should be
taken into account when interpreting the coefﬁcients.
Selection analysis
Genotyping
In total, 9912 ALSPAC children were genotyped using the
Illumina HumanHap550 quad genome-wide SNP genotyping
platform by Sample Logistics and Genotyping Facilities at the
Wellcome Trust Sanger Institute and LabCorp supported by
23andMe. Complete data for linkage disequilibrium (LD) ana-
lysis were available for 7583 unrelated individuals.
Statistical analyses
EHH was analysed as previously described.14 EHH measures
the decay of homozygosity at a core haplotype of interest.
Phased haplotypes involving rs28929474 and rs17580 plus 120
other SNPs (spanning ∼100 kb either side from rs28929474
and rs17580) were obtained by the software fastPHASE v1.227
from 7583 ALSPAC individuals. We used the Sweep program
for the identiﬁcation of core haplotypes involving the two SNPs
using the block deﬁnition from Gabriel et al.28
We used the Haplotter program13 to explore signatures of
selection in the SERPINA1 gene and surrounding genomic
region (of 1 Mb either side). To this end, Haplotter considers
data available for ∼800 000 common SNPs and 309 unrelated
individuals from three populations. This web tool displays the
results of selection from HapMap data by computing iHS, Fay
and Wu’s H, Tajima’s D and Fst.
13
RESULTS
Meta-analysis of HALCyon cohorts
For completeness, we show both RE and FE analyses. All ana-
lyses are given as online supporting information in the order:
SERPINA1 (see online supplementary tables S3–S35), CFTR (see
online supplementary tables S36–S40), ACADM (see online sup-
plementary tables S41–S43) and PAH (see online supplementary
tables S44–S46).
The genotype frequencies are provided in online supplemen-
tary tables S3–S5, S36, S41 and S44. There were no mutant
homozygote calls for CFTR, ACADM or PAH. There was limited
evidence for any carrier effect of K304E or the three PAH muta-
tions combined. There was weak evidence for a negative effect
of deltaF508 heterozygosity on height-adjusted FVC (see online
supplementary table S37). The individual cohort and
meta-analysed effect estimates for CFTR, ACADM and PAH are
provided in online supplementary tables S37–S46. Overall for
SERPINA1, there was no compelling evidence of an association
between PI status and physical capability (see online supplemen-
tary table S24). However, there was consistent evidence across
the cohorts for a respiratory difference of PI-MZ individuals
compared with MM individuals (table 2). No effect was
observed in PI-MS individuals. The estimated variance of the
RE of carrier status on FEV1 and FVC in the RE one-step
meta-analysis was very small, suggesting a ﬁxed carrier effect
across cohorts. The FEs estimate was a 0.13 SD increase in
FEV1 (p=1.7×10−5) and a 0.16 SD increase in FVC
(p=5.2×10−8) using IPD data from all eight cohorts. Taking
the study SDs and multiplying by these coefﬁcients, this corre-
sponds to a difference of approximately 81–108 mL (FEV1) and
115–170 mL (FVC). There was no association with FEV1/FVC
ratio (see online supplementary table S6). Our analysis of the
possible effect of smoking is shown in ﬁgure 1 (see online sup-
plementary tables S10–S15). Stratifying as current (N=2430),
ex (N=6422) and never (N=5473) smokers, there was no evi-
dence for a difference in PI-MZ effect by smoking status.
Considering the well-known correlation of lung function with
height,23 additional models adjusted for height were run for the
AAT variants (see online supplementary table S17). We initially
adjusted for height and height-squared (theoretically considering
respiratory surface area), with additional adjustments for height-
cubed (theoretically considering total respiring cell mass; see
online supplementary table S22). Empirically, FEV1 and FVC
depend on powers of height in the range 2.1–2.4 (Global Lung
Function Initiative prediction equations23). The association of
PI-MZ status with FEV1 and FVC was attenuated after adjust-
ment for powers of height (height and height-squared, table 3),
but approximately half of the effect remained, suggestive that
height and lung function are partially related covariates of
PI-MZ. Including height-cubed did not further attenuate the
genotypic association. We also considered the unadjusted PI-MZ
association (FE meta-analysis) with percentage of predicted
FEV1 or FVC using the Global Lungs Initiative ERS Task Force
2012 regression equations23 used in the COPD classiﬁcation.
This resulted in a slight attenuation of the association with
FEV1 (1.3% increase, p=0.09) and FVC (1.6% increase,
p=0.02). While the prediction equations could be accounting
for height in a purer way to covariate adjustment, they produced
percentage of predicted values lower than 100% in HALCyon
never smokers, which indicates that prediction equations speciﬁc
to this sample of British ageing individuals of European ancestry
may be required. The question of whether PI-MZ exerts a pleio-
tropic effect of enhanced respiratory capacity independently of
its height association thus requires further investigation.
The linear association between PI-MZ and height, adjusted
for age and sex (table 4), was notable (p=3.6×10−10, FE ana-
lysis) but was not observed for PI-MS. MZ individuals averaged
approximately 1.5 cm taller than MM individuals. The FE and
RE meta-analyses were repeated in individuals <55 years of age.
The coefﬁcient was reduced slightly (1.3 cm increase in MZ,
p=0.005, n=4552 FE analysis of four cohorts), but contained
the CI including all eight cohorts. We, therefore, concluded that
the PI-MZ effect on height represents a growth not age-related
shrinkage effect. There is also some hint (see online supplemen-
tary table S27) that mean height may increase across genotypes
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MM;MZ;SZ;ZZ. The association of PI-MZ versus MM and
height was additionally simultaneously adjusted for FVC and
FEV, which attenuated but did not remove the association (see
online supplementary table S29). We note that both the respira-
tory and height associations occur in geographically conﬁned
cohorts. The by-cohort analyses show no evidence for a
geographically stratiﬁed effect. The PI-MZ age-adjusted and sex-
adjusted associations with height, FEV1 z-score and FVC
z-score did not appear to be driven by population stratiﬁcation
when we ran models adjusted for principal components in four
of the studies (subsamples of ELSA, WHII, CaPS and LBC1921
with principal components available), although sample size was
Table 2 Association of alpha 1-antitrypsin protease inhibitor (PI) status with standardised lung function adjusted for age and sex
Regression coefficient (95% CI)
Outcome Cohort MS vs MM MZ vs MM†
Maximum FEV1 BO −0.05 (−0.36 to 0.27) 0.45 (−0.14 to 1.04)
CaPS 0.07 (−0.10 to 0.24) 0.11 (−0.12 to 0.33)
ELSA 0.05 (−0.03 to 0.12) 0.12* (0.01 to 0.23)
HAS −0.49* (−0.94 to −0.05) 0.08 (−0.39 to 0.55)
HCS −0.01 (−0.10 to 0.09) 0.05 (−0.10 to 0.19)
LBC1921 −0.06 (−0.31 to 0.19) 0.16 (−0.22 to 0.54)
NSHD 0.02 (−0.09 to 0.13) 0.18* (0.01 to 0.35)
WHII 0.05 (−0.03 to 0.12) 0.18** (0.06 to 0.29)
Combined FE 0.03 (−0.01 to 0.07) 0.13**** (0.07 to 0.19)
Combined RE 0.03 (−0.01 to 0.07) 0.13**** (0.07 to 0.19)
Estimated var‡ 1.20e−13 (0.00e+00 to .) 1.09e−19 (0.00e+00 to .)
Maximum FVC BO 0.03 (−0.26 to 0.32) 0.43 (−0.11 to 0.97)
CaPS 0.08 (−0.10 to 0.26) 0.15 (−0.09 to 0.39)
ELSA 0.02 (−0.05 to 0.09) 0.12* (0.01 to 0.22)
HAS −0.35 (−0.73 to 0.03) 0.33 (−0.09 to 0.74)
HCS −0.02 (−0.11 to 0.07) 0.14* (0.01 to 0.27)
LBC1921 −0.07 (−0.32 to 0.17) 0.20 (−0.17 to 0.56)
NSHD 0.02 (−0.09 to 0.13) 0.20* (0.04 to 0.37)
WHII −0.01 (−0.08 to 0.07) 0.19** (0.07 to 0.30)
Combined FE 0.01 (−0.03 to 0.04) 0.16**** (0.10 to 0.22)
Combined RE 0.00 (−0.04 to 0.04) 0.16**** (0.10 to 0.22)
Estimated var‡ 3.76e−15 (1.01e−28 to 1.40e−01) 3.53e−19 (0.00e+00 to .)
Estimates for PI-SS, SZ and ZZ are provided in the online supplement.
*p<0.05, **p<0.01, ***p<0.001, ****p<0.0001.
†Exact p values for PI-MZ-FEV1 were 1.7×10−5 (FE) and 1.1×10−5 (RE); for PI-MZ-FVC were 5.2×10−8 (FE) and 3.2×10−8 (RE).
‡Estimated variance of the random slope on carrier status modelled by the RE model.
BO, Boyd Orr; CaPS, Caerphilly Prospective Study; ELSA, English Longitudinal Study of Ageing; FE, fixed effect; FEV1, forced expiratory volume in 1 second; FVC, forced vital capacity;
HAS; Hertfordshire Ageing Study; HCS, Hertfordshire Cohort Study; LBC1921, Lothian Birth Cohort 1921; NSHD, MRC National Survey of Health and Development; RE, random effect;
WHII, Whitehall II Study.
Figure 1 Regression coefﬁcients from
ﬁxed effects one-step meta-analysis of
protease inhibitor-MZ effect on lung
function (z-scored within cohorts)
adjusted for age and sex. Estimates
from analyses stratiﬁed by smoking
status are also provided (current
smokers N=2430; ex smokers N=6422;
never smokers N=5473).38 FEV1,
forced expiratory volume in 1 second;
FVC, forced vital capacity.
284 North T-L, et al. J Med Genet 2016;53:280–288. doi:10.1136/jmedgenet-2015-103342
Complex traits
group.bmj.com on October 12, 2016 - Published by http://jmg.bmj.com/Downloaded from 
markedly attenuated. A homogeneity analysis (χ2 contingency
test) to test whether genotype frequencies of AAT deﬁciency PI
status differ among cohorts did not reveal signiﬁcant heterogen-
eity (p=0.310). Nominal but minor differences between
observed and expected genotype frequencies were observed for
HAS (contributions to χ2>3.84), but these are related to low
numbers and may be explained as type I error. We concluded
that the PI-Z allele may have pleiotropic effects on height and
respiratory function (ﬁgure 2).
The association of PI-MZ with weight and BMI was assessed
(see online supplementary tables S31–S35). We observed no
association for BMI and an effect estimate for weight that was
consistent with what is predicted given the observational correl-
ation between height and weight.
A previous population-based study showed a lower FEV1 in
PI-MZ compared with PI-MM in individuals with clinically
deﬁned COPD, adjusted for age, sex, height and smoking
status.29 Using the Global Lungs Initiative ERS Task Force 2012
regression equations,23 we classiﬁed all individuals as either
cases or non-cases for COPD and reran the age-adjusted and
sex-adjusted model in COPD cases (see online supplementary
tables S16, S19 and S20). We did not replicate the results of the
Table 3 Association of alpha 1-antitrypsin protease inhibitor
(PI)-MZ status and standardised lung function adjusted for age, sex,
height and height-squared
Outcome Cohort Regression coefficient (95% CI)
Maximum FEV1 BO 0.17 (−0.40 to 0.74)
CaPS 0.09 (−0.12 to 0.30)
ELSA 0.06 (−0.05 to 0.16)
HAS 0.11 (−0.34 to 0.56)
HCS −0.01 (−0.15 to 0.12)
LBC1921 0.09 (−0.27 to 0.44)
NSHD 0.08 (−0.08 to 0.23)
WHII 0.11 (−0.00 to 0.21)
Combined FE 0.07* (0.01 to 0.12)
Combined RE 0.07* (0.01 to 0.12)
Estimated var† 1.03e−17 (1.80e−32 to 5.87e−03)
Maximum FVC BO 0.06 (−0.43 to 0.56)
CaPS 0.13 (−0.08 to 0.34)
ELSA 0.04 (−0.06 to 0.14)
HAS 0.35 (−0.04 to 0.74)
HCS 0.07 (−0.05 to 0.18)
LBC1921 0.10 (−0.23 to 0.44)
NSHD 0.08 (−0.06 to 0.23)
WHII 0.10 (−0.00 to 0.20)
Combined FE 0.08** (0.03 to 0.13)
Combined RE 0.08** (0.03 to 0.13)
Estimated var† 1.25e−13 (5.20e−27 to 3.01e+00)
*p<0.05, **p<0.01, ***p<0.001, ****p<0.0001.
†Estimated variance of the random slope on carrier status modelled by the RE model.
BO, Boyd Orr; CaPS, Caerphilly Prospective Study; ELSA, English Longitudinal Study of
Ageing; FE, fixed effect; FEV1, forced expiratory volume in 1 second; FVC, forced vital
capacity; HAS; Hertfordshire Ageing Study; HCS, Hertfordshire Cohort Study; LBC1921,
Lothian Birth Cohort 1921; NSHD, MRC National Survey of Health and Development;
RE, random effect; WHII, Whitehall II Study.
Table 4 Association of alpha 1-antitrypsin protease inhibitor (PI) status and height (cm) adjusted for age and sex
Regression coefficient (95% CI)
Cohort MS vs MM MZ vs MM†
BO 2.31 (−0.24 to 4.86) 7.33** (2.36 to 12.30)
CaPS 0.27 (−0.97 to 1.51) 0.55 (−1.08 to 2.18)
ELSA 0.20 (−0.40 to 0.81) 2.02**** (1.12 to 2.92)
HAS 0.24 (−3.04 to 3.51) −0.26 (−3.69 to 3.18)
HCS −0.10 (−0.87 to 0.67) 1.23* (0.09 to 2.37)
LBC1921 0.44 (−1.55 to 2.43) 1.06 (−1.89 to 4.00)
NSHD 0.68 (−0.11 to 1.47) 1.84** (0.64 to 3.04)
WHII 0.23 (−0.34 to 0.81) 1.24** (0.34 to 2.14)
Combined FE 0.28 (−0.03 to 0.59) 1.50**** (1.03 to 1.97)
Combined RE 0.28 (−0.03 to 0.59) 1.51**** (1.04 to 1.97)
Estimated var‡ 2.77e−13 (1.06e−26 to 7.27e+00) 1.67e−12 (1.59e−25 to 1.76e+01)
Estimates for PI-SS, SZ and ZZ are provided in the online supplement.
*p<0.05, **p<0.01, ***p<0.001, ****p<0.0001.
†Exact p values for PI-MZ—height were 3.6×10−10 (FE) and 2.9×10−10 (RE).
‡Estimated variance of the random slope on carrier status modelled by the RE model.
BO, Boyd Orr; CaPS, Caerphilly Prospective Study; ELSA, English Longitudinal Study of Ageing; FE, fixed effect; HAS; Hertfordshire Ageing Study; HCS, Hertfordshire Cohort Study;
LBC1921, Lothian Birth Cohort 1921; NSHD, MRC National Survey of Health and Development; RE, random effect; WHII, Whitehall II Study.
Figure 2 The pleiotropic effect of the Z allele on respiratory capacity
and height. ‘Unadjusted’ estimates are from the (upper circle) one-step
ﬁxed effects analyses of z-scored forced expiratory volume in 1 second
(FEV1) or z-scored forced vital capacity (FVC) on protease inhibitor
(PI)-MZ versus PI-MM adjusted for age and sex or (lower circle) from
the one-step ﬁxed effects analysis of height (cm) on PI-MZ versus
PI-MM adjusted for age and sex. The ‘adjusted’ estimates are
additionally adjusted for (upper circle) height (cm) and (lower circle)
z-scored FEV1 and z-scored FVC simultaneously.
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previous study, nor after adjustment for powers of height and
smoking status. We meta-analysed the odds of COPD in PI
classes compared with MM individuals (see online supplemen-
tary tables S25 and S26). There was no compelling evidence for
an association with PI-MS or PI-MZ, while the PI-SS, SZ and
PI-ZZ meta-analyses were not possible due to the low genotype
frequencies. However, two out of six ZZs with available data
displayed COPD (one extreme).
Online supplementary table S2 shows that overall we con-
ducted in the region of 182 one-step meta-analyses across all
outcomes and genetic variants. Many of these tests were not
independent due to the outcomes (eg, FEV1/FVC ratio is
derived from FEV1 and FVC) or the genetic exposures (eg,
PI-MM were included in all PI analyses) or due to subgroup
analyses (eg, smokers, COPD) or rerunning adjusted models.
However, even with a Bonferroni adjustment based on this
number (p=0.00027), our main results still produce compara-
tively small p values. The results of further sensitivity analyses
are described in online supplementary appendix S4.
Selection analysis
EHH results involving rs28929474 and rs17580 show small
decay of EHH, from 1 to 0.6, after 90 kb from 50 (see online
supplementary ﬁgure S1). This relatively small reduction is
observed for two rare haplotypes (of 5% and 2% frequency,
respectively) each of them including the rare allele of each SNP.
The decay of EHH is more pronounced to the 30 end, with
EHH for both rare haplotypes being reduced to 0.5 at a dis-
tance of 30 kb. These results were qualitatively unchanged with
the addition of neighbouring SNPs to the core region.
Results observed from Haplotter for common SNPs analysed
by iHS, Fay and Wu’s H, Tajima’s D and Fst show no evidence
of selection driving alleles at intermediate or high frequency in
and around the SERPINA1 gene (see online supplementary
ﬁgure S2).
Recombination data from the ALSPAC sample combined with
pairwise LD between SNPs around rs28929474 suggested an
allele age of between 100 and 250 generations (see online sup-
plementary ﬁgure S3). In contrast, using Z allele frequency this
estimate was 1758 generations.
DISCUSSION
The PI-MZ rare (2%) SNP height effect is about fourfold
greater than that for the top common SNP in HMGA2 for
height. However, PI-MZ is not represented on GWAS chips, so
the largest height meta-analyses of up to 250 000 individuals30
would not have detected it directly and apparently did not do
so by imputation. Furthermore, whole-genome sequencing
studies such as UK10K (http://www.UK10K.org) would not have
analysed enough individuals to robustly detect the effect even if
calls and imputation on low read depth were efﬁcient. While
analyses of the possible contribution of common SNPs to height
suggest that they could explain the large part of this highly her-
itable trait,31 our observation raises the possibility that many
common SNPs might be each weakly proxying rarer causal
alleles.
Our main results of interest (MZ carrier effect on lung func-
tion and height) were obtained from a large number of carriers
(>600) at the meta-analysis level. Neither association explains
the other, although there is partial phenotypic correlation. The
enhancement (rather than reduction) of FEV1 and FVC by PI-Z
allele heterozygosity was unexpected and is in apparent contrast
with the suggestion of greater incidence of respiratory infections
in PI-MZ children20 and with the well-known severe deleterious
effects of PI-ZZ. However, mechanisms for balancing selection
on PI-MZ (rs28929474) have previously been proposed,32 and
the potential connective tissue and immunological/inﬂammatory
effects of the Z allele32 could plausibly lead to enhanced FEV1
and FVC with either positively or negatively correlated inﬂam-
matory or infection susceptibility. Previous studies have detected
an interaction of PI-MZ with smoking such that PI-MZ ever
smokers have reduced respiratory capacity compared with
PI-MM.33 Our analysis restricted to current smokers did not
detect reduced respiratory capacity in this group of individuals,
and we observed enhanced respiratory capacity in ex smokers.
Seventeen per cent of individuals with the relevant covariates
(PI status, lung function, age and sex) were current smokers in
HALCyon, 97 of which were PI-MZ. Future observational
studies with increased sample size should consider current or
ever smoking PI-MZ individuals to consider whether there is
reduced respiratory capacity in this subgroup of individuals.
Alternatively, it could be that a cumulative smoke exposure of
an as yet undetermined amount determines the development of
respiratory disease in PI-MZ individuals; there is evidence in
PI-ZZ and PI-SZ individuals that such a concept exists.4 34
Consequently, future studies may also need to quantify relevant
environmental exposures such as cigarette smoking.
Microsatellite dating of the Z allele suggests appearance 107–
135 generations ago, with high prevalence in North Europe.35
Height SNP variants have recently been shown collectively to
have been positively selected in North (vs South) Europeans.36
Using GWAS data and PI genotype status in another UK cohort,
ALSPAC,16 we analysed for EHH (see online supplementary
ﬁgure S1). We also tested selection related to common variation
around SERPINA1 from Haplotter13 (see online supplementary
ﬁgure S2) and estimated allele age based both on allele fre-
quency17 and on local recombination between the Z locus and
other SNPs. Recombination data in conjunction with pairwise
LD between SNPs around rs28929474 indicate an allele age
consistent with earlier microsatellite estimates (from 100 to 250
generations, see online supplementary ﬁgure S3), and even for a
rare SNP, the haplotypes on which Z and S reside are extended,
whereas Z allele frequency estimates an age about 10× older
(1758 generations). These genomic features all point towards
positive selection acting on the Z (and S) alleles. It is, therefore,
possible that PI-Z, here shown to be a rarer allele for greater
height, has been positively selected on height (or weight—a pos-
sible survival advantage in colder latitudes) though PI-ZZ is det-
rimental to respiratory health. PI-MZ may thus represent a
balanced polymorphism with greater height or FEV1 or FVC
being advantageous in heterozygotes but lung (and liver) disease
being disadvantageous in ZZ homozygotes.
AAT is a therapeutic agent and target in relation to its respira-
tory importance.37 Our ﬁndings in PI-MZ heterozygotes invite
both a reconsideration of what may be an optimal level of AAT
for best respiratory function and for the ﬁrst time a consider-
ation whether AAT may mark a novel aspect of height determin-
ation, which could itself become a therapeutic target for height
modiﬁcation in some growth deﬁciency disorders.
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